Related Experiment Video
Updated: Aug 30, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
The proteome of clear cell ovarian carcinoma
Jennifer X Ji1, Dawn R Cochrane2, Gian Luca Negri3
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Abstract:
Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late-stage CCOC is not responsive to gold-standard chemotherapy and results in suboptimal outcomes for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics for 192 cases of CCOC and compared these with other epithelial ovarian carcinoma subtypes. Our results showed distinct proteomic differences in CCOC compared with other epithelial ovarian cancer subtypes including alterations in lipid and purine metabolism pathways. Furthermore, we report potential clinically significant proteomic subgroups within CCOC, suggesting the biologic plausibility of stratified treatment for this cancer. Taken together, our results provide a comprehensive understanding of the CCOC proteomic landscape to facilitate future understanding and research of this disease. © 2022 The Pathological Society of Great Britain and Ireland.
Insights
This study reveals distinct proteomic differences in clear cell ovarian carcinoma (CCOC), identifying metabolic pathway alterations. These findings support potential for stratified treatment strategies in advanced CCOC.
Area of Science:
- Oncology
- Proteomics
- Metabolomics
Background:
- Clear cell ovarian carcinoma (CCOC) is the second most prevalent epithelial ovarian cancer subtype.
- Late-stage CCOC exhibits resistance to standard chemotherapy, leading to poor patient outcomes.
- A deeper molecular understanding is crucial for disease stratification and therapeutic advancement.
Purpose of the Study:
- To comprehensively analyze the proteomic landscape of CCOC.
- To identify proteomic distinctions between CCOC and other ovarian cancer subtypes.
- To explore potential proteomic subgroups for targeted therapeutic development.
Main Methods:
- Global proteomic analysis was performed on 192 CCOC cases.
- Proteomic data was compared across different epithelial ovarian carcinoma subtypes.
- Bioinformatic analysis was used to identify metabolic pathway alterations and subgroups.
Main Results:
- Significant proteomic differences were observed in CCOC compared to other ovarian cancer subtypes.
- Alterations in lipid and purine metabolism pathways were identified as key features of CCOC.
- Distinct proteomic subgroups within CCOC were discovered, indicating potential for personalized medicine.
Conclusions:
- The proteomic profiling provides a comprehensive understanding of the CCOC molecular characteristics.
- Identified metabolic alterations and subgroups offer a basis for developing novel therapeutic strategies.
- This research facilitates future investigations into CCOC biology and treatment.
